Gilead to buy Ouro Medicines for up to $2.2 billion [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition will cost Gilead $1.675 billion in upfront cash consideration, subject to customary adjustments, plus up to $500 million in contingent milestone payments. The deal adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager, to Gilead's inflammation portfolio. OM336, which has gotten both Fast Track and Orphan Drug Designation, is designed to enable rapid B cell depletion following subcutaneous treatment. In ongoing Phase 1/2 clinical studies, the drug has shown efficacy in severe autoimmune diseases including autoimmune hemolytic anemia and immune thrombocytopenia. Gilead plans to enter into a strategic collaboration with Galapagos on the Ouro portfolio. Under the proposed arrangement, Galapagos would pay 50% of the upfront consideration and milestone payments, absorb substantially all of Ouro's operating assets and retain its employees. Galapagos would be respon
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research [Yahoo! Finance]Yahoo! Finance
- Arcellx (ACLX) was upgraded by Truist Financial Corporation from "hold" to "strong-buy".MarketBeat
- $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—QETA, NIMU, ACLX, and FONRGlobeNewswire
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal [Yahoo! Finance]Yahoo! Finance
- Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?PR Newswire
ACLX
Earnings
- 2/26/26 - Miss
ACLX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/6/26 - Form SC
- ACLX's page on the SEC website